DDInter119 DDInter1588
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.
Ribociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Ribociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Ribociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tadalafil
Ribociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ripretinib
Ribociclib {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Ribociclib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Ribociclib may lead to a major life threatening interaction when taken with Enzalutamide
Ribociclib may lead to a major life threatening interaction when taken with Lurbinectedin